

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 17th July 2024 10-12pm

Microsoft Teams Meeting

Present:	Mehrdad Malekian (Chair) Penny Brankin Victoria Gemmell (Prof Sec) Tyra Smyth Kirsty Macfarlane Linda Johnstone Rachael Kelly Mark Kirk Gail Richardson Colin Angus Chris Miller Craig Thurtell Stephanie Dundas	
1. Apologies:	Kelly Baillie Alistair Brown	
2. Declaration of Interest	nil	
Item	Notes	Action
3.	<u>Minutes/Actions from the last meeting</u> Apologies to be added, and these were accepted as a true record of the meeting.	
4.	<u>Matters Arising</u> a) SAPG Response to MHRA updated statement on use of fluoroquinolones – Progress update from Stephanie Dundas SD update-HEPMA prescribing system now has a live message to alert prescribers to the new considerations around patient information and consent at the point of prescribing of quinolones. b) Freestyle Libre 3 guideline – update awaited Liz McIntyre This was discussed. Some small updates requested. Question regarding distribution-it was agreed that it should be accessible via keyword search on the Guidelines website. Question on funding-currently via SG. The service will be required to confirm more details on this before this device can be recommend for prescribing. The group considered the flowchart to be helpful. The document is approved pending these changes. c) Asthma Biologics – update awaited Andrew This was discussed. The group welcomed this useful guidance. Some changes, including the transfer to the current Clinical guidelines template was requested. The document is NOT approved at this time.	

- d) Alteplase Infusion Chart – update Gail Richardson**
This is still under discussion and will be represented at a later date.
- e) EUCAST - update Stephanie Dundas**
Policies have been separated into acute and primary care policies for simplicity. The lab has added a clarification to reports generated due to a technical difficulty. This will be resolved in due course.
Two memos have been shared to alert teams to changes and an educational package has been developed to support the changes.
- f) Bimekizumab protocol – Sanjiv Nandwani**
Update awaited. Carried forward to August meeting
- g) Antimicrobial Policy Register SBAR - Steve McCormick**
SD confirmed that the documents still have relevant content and there is no other contradictory guidance. Any guidance that is out of date has been removed. A formal response confirming this is expected. There was discussion around the availability of some guidance on FirstPort/MEDED and the availability of the online calculators. MM will discuss this with the Library team.
POST MEETING NOTE
Email communication has been received and confirms the items will only migrate if they are still safe and fit for purpose
- h) Gastroscopy - Audrey McCallum**
Update awaited. Carried forward to August meeting
- i) Doxazosin for TRN - Mogese Abbas**
This was discussed. Some small changes requested.
Approved pending these changes.
There was also a request to ensure the initiating specialist has appropriate monitoring equipment available.
A previous request around potential cost was discussed. This is a low cost item with small patient numbers. The group was satisfied this will not place additional strain on current budgets.
- j) Migraine Treatment Pathway – Kirsty MacFarlane**
Feedback from specialist services and primary care was discussed.
Summary of discussion
 - Retain the option for referral to specialist service
 - Emphasise the need to try each medicine listed before moving to the newer agents
 - MHRA advice regarding topiramate to be highlighted
 - Further comments received will be incorporated
This was approved pending these small amendments.
- k) Additional Paper-HF Guidance-Update Mehrdad Malekian**
This was discussed. Several changes requested.

	Final version to return for noting.	
5.	<p><u>SMC Advice-CONFIDENTIAL</u></p> <p>Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 2.00 pm on Monday 12 August 2024.</p> <p><u>Full Submissions</u></p> <ul style="list-style-type: none"> • etranacogene dezaparvovec concentrate for solution for infusion (Hemgenix) CSL Behring UK Limited SMC2649 for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors ACCEPTED ON INTERIM BASIS with PAS. Await guidance from GGC • trifluridine/tipiracil film-coated tablets (Lonsurf) Servier Laboratories Limited SMC2654 in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents. ACCEPTED with PAS Await guidance from WoSCAN <p><u>Non submissions-For Noting</u></p> <ul style="list-style-type: none"> • fezolinetant film-coated tablets (Veoza) Astellas Pharma Ltd SMC2702 • nivolumab concentrate for solution for infusion (Opdivo) Bristol-Myers Squibb Pharmaceuticals Ltd SMC2704 • talquetamab solution for injection (Talvey) Janssen-Cilag Ltd SMC2705 • trastuzumab deruxtecan powder for concentrate for solution for infusion (Enhertu) Daiichi Sankyo UK Limited SMC2706 <p><u>Amended advice-For Noting</u></p> <ul style="list-style-type: none"> • <u>empagliflozin</u> film-coated tablets (Jardiance®) Boehringer Ingelheim SMC2642 	
6.	<p><u>SMC follow up</u></p> <p>RK presented the July follow-up which had been previously circulated. All updates to designations were agreed by the committee. RK explained where work is ongoing to liaise with specialist teams for subsequent meetings.</p>	RK
7.	<p><u>Lanarkshire Formulary</u></p> <p>RK presented the NHSL Formulary Amendment paper which detailed the addition of a small number of messages to the formulary, regarding medication shortages and discontinuations. The Formulary Amendment Request form for Sitagliptin was discussed and agreed, which detailed a change in formulary preference of DPP-4 inhibitor to Sitagliptin. Work will now proceed around this by the Formulary and Clinical Effectiveness pharmacist.</p> <p>A proposed formulary statement regarding the recent MHRA Drug Safety Update for Topiramate and the Pregnancy Prevention Programme was presented by RK. This was agreed, and the committee agreed will now be added to the Formulary, along with messages for ScriptSwitch and Vision Guidelines.</p>	RK

<p>8.</p> <p>(a)</p> <p>(b)</p> <p>(c)</p> <p>(d)</p> <p>(e)</p>	<p><u>Clinical Protocols</u></p> <p>Items which should not be prescribed in NHSL - Emma Harris This was approved.</p> <p>Maternity Varicella in pregnancy guideline - Hannah Fulton 1.20 This guideline was produced in response to a change in current treatment advice for this patient group. It was agreed that is a helpful guideline and should be shared widely once approved. Summary of requested changes-</p> <ul style="list-style-type: none"> ○ Definition of roles and responsibilities needs further detail ○ Clarity was requested around if this is a change to current practice regarding place of treatment. ○ A need for a patient treatment pathway was identified and should be included as part of this guidance. ○ A need was identified for wider consultation with primary care and ID teams. <p>The document was NOT approved at this time</p> <p>Paediatric PCA / Postop Pain Guideline – Sharon Anderson This is an update to a previous version. This was discussed and a number of changes requested. The document is NOT approved at this time.</p> <p>Ritlecitinib - Carole Martin The protocol for this medicine was approved on clinical grounds by ADTC, and will proceed through standard procedures for evaluation and consideration of cost and service implications.</p> <p>Clotrimazole - Steve McCormick (Updates to Primary Care Empirical Policy Content) This a request for interim updates to current NHSL policies in line with National Guidance. This was discussed and a small change requested. Additionally, SD to confirm if messages could be added to lab results regarding treatment. Approved pending this change. To be shared via Prescribing notes, GP practice communications and via Antimicrobial Teams and ScriptSwitch.</p>	
<p>9.</p>	<p><u>ADTC New Medicines Decisions</u> RK presented New Medicines Decisions bulletins which comprised medicines from June's ADTC meeting, as well as updates to previous bulletins from earlier in 2024 and 2023. These bulletins will now be sent to the Clinical Guidelines team for publishing.</p>	
<p>10.</p> <p>(a)</p>	<p><u>Unlicensed Medicines</u></p> <p>Lanarkshire ULM Medicines Policy. This was approved.</p>	

11.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update Topiramate-additional paper circulated detailing potential changes to Joint Formulary Webpage based on updated MHRA advice. This was discussed and accepted with no changes. Safety messages will be added to NHSL Joint Formulary, Vision Guidelines tab and ScriptSwitch</p>	
12.	<p><u>Regional Cancer Advisory Network</u> These were noted</p>	
13.	<p><u>Patient Safety Alerts</u> NPSA Alert-PERT Products An Update was given; the situation seems to be resolving.</p>	
14.	<p><u>Lay member related items</u> NIL</p>	
15.	<p><u>Correspondence</u> (a) <u>ADTC Collaborative</u> (i) <u>ADTCC newsletter</u> This was noted (ii) <u>NCMAG-Off Label use of Dasatinib</u> This was noted</p>	
16.	<p><u>Pharmacy & NMAHP Prescribing Governance</u> NIL</p>	
17.	<p><u>AOCB</u> (a) <u>IVIG Request Form</u> It was agreed that a link would be helpful here instead of an original document</p>	
18.	<p><u>Date of next meeting</u> Wednesday 21st August 2024 10-12pm MS TEAMS</p>	